Stryker price target raised to $345 from $320 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Stryker to $345 from $320 and keeps an Equal Weight rating on the shares. Stryker is “coming off another strong year” and enters 2024 “well positioned to once again deliver top-tier MedTech growth,” says the firm, though it remains Equal Weight rated on the stock as it says its estimates largely reflect the consensus view.